ATE375518T1 - Diagnoseverfahren für erkrankungen unter verwendung von copeptin - Google Patents

Diagnoseverfahren für erkrankungen unter verwendung von copeptin

Info

Publication number
ATE375518T1
ATE375518T1 AT05782853T AT05782853T ATE375518T1 AT E375518 T1 ATE375518 T1 AT E375518T1 AT 05782853 T AT05782853 T AT 05782853T AT 05782853 T AT05782853 T AT 05782853T AT E375518 T1 ATE375518 T1 AT E375518T1
Authority
AT
Austria
Prior art keywords
copeptin
diseases
diagnostic methods
diagnostic
methods
Prior art date
Application number
AT05782853T
Other languages
English (en)
Inventor
Andreas Bergmann
Joachim Struck
Original Assignee
Brahms Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brahms Ag filed Critical Brahms Ag
Application granted granted Critical
Publication of ATE375518T1 publication Critical patent/ATE375518T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5757—Vasoactive intestinal peptide [VIP] or related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/15—Oxytocin or vasopressin; related peptides
AT05782853T 2004-08-19 2005-08-19 Diagnoseverfahren für erkrankungen unter verwendung von copeptin ATE375518T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20040019732 EP1628136A1 (de) 2004-08-19 2004-08-19 Diagnoseverfahren für Krankheiten unter Verwendung von Copeptin

Publications (1)

Publication Number Publication Date
ATE375518T1 true ATE375518T1 (de) 2007-10-15

Family

ID=34926232

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05782853T ATE375518T1 (de) 2004-08-19 2005-08-19 Diagnoseverfahren für erkrankungen unter verwendung von copeptin

Country Status (11)

Country Link
US (3) US7807397B2 (de)
EP (2) EP1628136A1 (de)
JP (2) JP4932714B2 (de)
CN (2) CN102539789B (de)
AR (1) AR050215A1 (de)
AT (1) ATE375518T1 (de)
DE (1) DE602005002836T2 (de)
ES (1) ES2296224T3 (de)
HK (2) HK1114171A1 (de)
MX (1) MXPA06014775A (de)
WO (1) WO2006018315A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140046407A1 (en) * 2001-08-31 2014-02-13 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
DE102006034142A1 (de) 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Verfahren zur Steuerung der Therapie von Patienten mit Herzinsuffizienz anhand der vitro Bestimmung von Schwellenwerten von vasoaktiven Peptiden
DE102006046996A1 (de) * 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
EP2544001A3 (de) * 2006-10-18 2013-04-24 Axela Inc. Messung mehrerer Analyten über einen breiten Bereich von Konzentrationen unter Verwendung von optischer Brechung
PL2084543T3 (pl) 2006-10-26 2018-04-30 B.R.A.H.M.S Gmbh Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II
DE102006050497A1 (de) * 2006-10-26 2008-04-30 Brahms Aktiengesellschaft Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II
DE102006053442A1 (de) 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
DE102006058266A1 (de) * 2006-12-08 2008-06-12 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz mittels Neurophysin
EP2180322A1 (de) * 2008-10-22 2010-04-28 BRAHMS Aktiengesellschaft Prognostische Biomarker zur Progression von primär chronischen Nierenerkrankungen
ES2645688T3 (es) * 2008-10-31 2017-12-07 B.R.A.H.M.S Gmbh Prohormona arginina-vasopresina como biomarcador predictivo de la diabetes
US20100312581A1 (en) * 2009-06-08 2010-12-09 Peter James Wachtell Process and system for efficient allocation of medical resources
WO2010146064A1 (en) 2009-06-16 2010-12-23 B.R.A.H.M.S Gmbh Diagnostical use of peroxiredoxin 4
US20140051183A1 (en) * 2010-06-18 2014-02-20 B.R.A.H.M.S Gmbh Biomarkers for the prediction of incident cancer
WO2012162679A1 (en) 2011-05-26 2012-11-29 Phoenix Pharmaceuticals, Inc. Phoenixin peptides
EP2541252A1 (de) 2011-06-30 2013-01-02 B.R.A.H.M.S GmbH Verfahren zum Erhalten eines Binders für Preprovasopressin oder Fragmente davon
AU2012335610A1 (en) 2011-11-11 2014-06-12 Woomera Therapeutics Provasopressin antagonists and uses thereof
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US11391742B2 (en) 2015-02-10 2022-07-19 B.R.A.H.M.S. Gmbh Free histone proteins as biomarkers
EP3279667A1 (de) 2016-08-02 2018-02-07 Abbott Laboratories Herz-troponin i und copeptin als biomarker für kurzfristige sterblichkeit bei akuter exazerbation von chronisch obstruktiver lungenerkrankung (aecopd)
CN109061140A (zh) * 2018-08-31 2018-12-21 广州华澳生物科技有限公司 一种和肽素免疫层析检测试剂卡及其制备方法
CN109679924A (zh) * 2018-12-25 2019-04-26 广州万孚生物技术股份有限公司 高亲和力抗人和肽素的单克隆抗体及其制备方法与应用
CN109596839A (zh) * 2018-12-25 2019-04-09 广州万孚生物技术股份有限公司 人和肽素快速定量检测方法与试剂盒
EP3918343A1 (de) * 2019-01-28 2021-12-08 B.R.A.H.M.S GmbH Verfahren zur vorhersage der behandlungsreaktion bei patienten mit nächtlicher enurese
CN111007270A (zh) * 2019-11-27 2020-04-14 迪瑞医疗科技股份有限公司 和肽素化学发光免疫检测试剂盒及其制备方法
CN113406339A (zh) * 2021-08-19 2021-09-17 山东康华生物医疗科技股份有限公司 一种干式免疫荧光定量法人和肽素（cpp）检测试剂盒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413783B1 (en) * 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
US6822082B2 (en) * 2000-06-30 2004-11-23 Zymogenetics, Inc. Polynucleotides for mammalian secreted protein, Z1055G2P
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
CN1166953C (zh) * 2001-05-30 2004-09-15 上海晶泰生物技术有限公司 一步法多指标检测心肌梗塞的快速金标检测试剂盒
JP4124734B2 (ja) * 2001-11-26 2008-07-23 アスビオファーマ株式会社 経鼻吸収用医薬組成物
US7790162B2 (en) * 2002-07-16 2010-09-07 Woomera Therapeutics, Inc. Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells
WO2004058055A2 (en) * 2002-12-24 2004-07-15 Biosite Incorporated Method and system for disease detection using marker combinations
PL2084543T3 (pl) * 2006-10-26 2018-04-30 B.R.A.H.M.S Gmbh Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II
DE102006053442A1 (de) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
DE102006060112A1 (de) * 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
DE102007010834A1 (de) * 2007-03-03 2008-09-04 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten

Also Published As

Publication number Publication date
EP1738178B1 (de) 2007-10-10
DE602005002836D1 (de) 2007-11-22
CN101010591A (zh) 2007-08-01
JP2011227095A (ja) 2011-11-10
ES2296224T3 (es) 2008-04-16
US20170242037A1 (en) 2017-08-24
CN101010591B (zh) 2011-12-21
JP4932714B2 (ja) 2012-05-16
AR050215A1 (es) 2006-10-04
HK1114171A1 (en) 2008-10-24
WO2006018315A1 (en) 2006-02-23
CN102539789B (zh) 2015-04-08
HK1172690A1 (en) 2013-04-26
JP2008510151A (ja) 2008-04-03
CN102539789A (zh) 2012-07-04
US7807397B2 (en) 2010-10-05
EP1738178A1 (de) 2007-01-03
US20110008911A1 (en) 2011-01-13
US20090221009A1 (en) 2009-09-03
EP1628136A1 (de) 2006-02-22
DE602005002836T2 (de) 2008-07-31
MXPA06014775A (es) 2007-03-23

Similar Documents

Publication Publication Date Title
ATE375518T1 (de) Diagnoseverfahren für erkrankungen unter verwendung von copeptin
DE602006020135D1 (de) Dialogverwaltung unter verwendung von skripts
DK1879623T3 (da) Genterapi til rygmarvssygdomme
DE602005018406D1 (de) Reinigungsmethode für Antikörper
DE602005020209D1 (de) System zur Evaluierung von Herzstörungen
DE602005018414D1 (de) Betätigungseinrichtung für ein endoskopisches Gerät zum Anbringen von Klammern
DK1748077T3 (da) Fremgangsmåde til fremstilling af protein
NO20071430L (no) Anti-OX4OL antistoffer
DE602005013819D1 (de) Pyridincarbonsäureamidderivate zur verwendung als antikrebsmittel
DE602005026757D1 (de) Tonerherstellungsmethode
DE602005006185D1 (de) Entwicklungsverfahren
DE602005020768D1 (de) Flammfestes kunstleder
DE602004011334D1 (de) Rüttler für Zellkulturklimaschrank
ME01459B (me) Postupak za doziranje medikamenata
DE602005021793D1 (de) Abgasrückführungssystem unter verwendung von unein
DE102004001078B8 (de) Flugzeugrumpf
DE602006009513D1 (de) Verwendung von phenylsemicarbazonen für die saatgutbeizung
DE602005003123D1 (de) Radaraltimeter für hängelasttransportierende helikopter
DE602005007817D1 (de) Analyse-Verfahren unter Verwendung von abgeschwächter Totalreflektion
DE602004011962D1 (de) Armstütze für Operateur
ATE414796T1 (de) Mittel zur herstellung von leder
DK3467112T3 (da) Fremgangsmåder til transfektion af nukleinsyrer til levende celler
DE502005004788D1 (de) Beleuchtungseinheit für Flugzeuge
DE502005002528D1 (de) Elektrolysevorrichtung zur herstellung von alkalimetall
DE112005001782A5 (de) Anschlussteil für Prothesen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1738178

Country of ref document: EP